HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.

AbstractPURPOSE:
The efficacy of lapatinib versus trastuzumab combined with taxanes in the first-line setting of human epidermal growth factor receptor 2 (HER2) -positive metastatic breast cancer (BC) is unknown.
PATIENTS AND METHODS:
The MA.31 trial compared a combination of first-line anti-HER2 therapy (lapatinib or trastuzumab) and taxane therapy for 24 weeks, followed by the same anti-HER2 monotherapy until progression. Stratification was by prior (neo)adjuvant anti-HER2 therapy, prior (neo)adjuvant taxane, planned taxane, and liver metastases. The primary end point was intention-to-treat (ITT) progression-free survival (PFS), defined as time from random assignment to progression by RECIST (version 1.0) criteria, or death for patients with locally assessed HER2-positive tumors. The primary test statistic was a stratified log-rank test for noninferiority. PFS was also assessed for patients with centrally confirmed HER2-positive tumors.
RESULTS:
From July 17, 2008, to December 1, 2011, 652 patients were accrued from 21 countries, resulting in 537 patients with centrally confirmed HER2-positive tumors. Median follow-up was 21.5 months. Median ITT PFS was 9.0 months with lapatinib and 11.3 months with trastuzumab. By ITT analysis, PFS was inferior for lapatinib compared with trastuzumab, with a stratified hazard ratio (HR) of 1.37 (95% CI, 1.13 to 1.65; P = .001). In patients with centrally confirmed HER2-positive tumors, median PFS was 9.1 months with lapatinib and 13.6 months with trastuzumab (HR, 1.48; 95% CI, 1.20 to 1.83; P < .001). More grade 3 or 4 diarrhea and rash were observed with lapatinib (P < .001). PFS results were supported by the secondary end point of overall survival, with an ITT HR of 1.28 (95% CI, 0.95 to 1.72; P = .11); in patients with centrally confirmed HER2-positive tumors, the HR was 1.47 (95% CI, 1.03 to 2.09; P = .03).
CONCLUSION:
As first-line therapy for HER2-positive metastatic BC, lapatinib combined with taxane was associated with shorter PFS and more toxicity compared with trastuzumab combined with taxane.
AuthorsKaren A Gelmon, Frances M Boyle, Bella Kaufman, David G Huntsman, Alexey Manikhas, Angelo Di Leo, Miguel Martin, Lee S Schwartzberg, Julie Lemieux, Samuel Aparicio, Lois E Shepherd, Susan Dent, Susan L Ellard, Katia Tonkin, Kathleen I Pritchard, Timothy J Whelan, Dora Nomikos, Arnd Nusch, Robert E Coleman, Hirofumi Mukai, Sergei Tjulandin, Rustem Khasanov, Shulamith Rizel, Anne P Connor, Sergio L Santillana, Judith-Anne W Chapman, Wendy R Parulekar
JournalJournal of clinical oncology : official journal of the American Society of Clinical Oncology (J Clin Oncol) Vol. 33 Issue 14 Pg. 1574-83 (May 10 2015) ISSN: 1527-7755 [Electronic] United States
PMID25779558 (Publication Type: Clinical Trial, Phase III, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Copyright© 2015 by American Society of Clinical Oncology.
Chemical References
  • Antibodies, Monoclonal, Humanized
  • Biomarkers, Tumor
  • Bridged Compounds
  • Quinazolines
  • Taxoids
  • lapatinib
  • taxane
  • ERBB2 protein, human
  • Receptor, ErbB-2
  • Trastuzumab
Topics
  • Adult
  • Aged
  • Antibodies, Monoclonal, Humanized (administration & dosage)
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Biomarkers, Tumor (analysis)
  • Breast Neoplasms (chemistry, drug therapy, pathology)
  • Bridged Compounds (administration & dosage)
  • Diarrhea (chemically induced)
  • Disease-Free Survival
  • Drug Administration Schedule
  • Drug Eruptions (etiology)
  • Female
  • Follow-Up Studies
  • Humans
  • International Cooperation
  • Kaplan-Meier Estimate
  • Middle Aged
  • Neoplasm Staging
  • Patient Selection
  • Quality of Life
  • Quinazolines (administration & dosage, adverse effects)
  • Receptor, ErbB-2 (analysis)
  • Taxoids (administration & dosage)
  • Trastuzumab
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: